Diagnostic Products Corporation Announces Third Quarter Sales and Earnings
24 Ottobre 2005 - 2:00PM
Business Wire
Diagnostic Products Corporation (NYSE:DP) today reported third
quarter sales of $116.3 million, a 7% increase over the third
quarter of 2004. Sales for the nine months ending September 30,
2005 were $354.7 million, an increase of 9% over the same period in
2004. Earnings for the quarter were $17.1 million, or $.56 per
diluted share, up from $16.5 million or $.55 reported for the third
quarter of 2004. Earnings for the nine months were $54.1 million or
$1.79 per diluted share versus $50.6 million or $1.69 per diluted
share in the same period in 2004. In the third quarter of 2005, the
Brazilian real strengthened relative to the dollar while the euro
weakened slightly, and the net effect of foreign currency movements
was a 2% increase in sales. In the first nine months of 2005 both
the real and the euro strengthened relative to the dollar and the
effect of currency movements was an increase in sales of 3%. In the
third quarter, domestic sales increased 15% to $37.1 million while
international sales grew at 3%. For the nine months, domestic sales
increased 13% to $106.3 million while international sales grew at
7%. Sales of IMMULITE products grew 8% over the third quarter of
2004. IMMULITE product line sales reached $107.7 million for the
quarter. IMMULITE reagent sales increased 7% this quarter over the
third quarter of 2004 to $91.9 million, and IMMULITE instrument and
service revenue increased by 16% to $15.8 million. Sales of RIA
products were $5.3 million, a 9% decline from last year's third
quarter. Sales of other products were $3.3 million, versus $3.5
million in the same period last year. "We were disappointed in the
reagent flow this quarter which is a reflection of the limited
number of tests released over the last year," said Michael Ziering,
CEO of DPC. "However, we have released three new tests on the 2500
for international markets in the last three months and are on track
to release proBNP internationally in November." The Company shipped
a total of 226 IMMULITE instruments in the third quarter including
146 IMMULITE 2000s and 2500s. The total number of IMMULITEs shipped
is now over 10,600. Diagnostic Products Corporation, founded in
1971, is a global leader dedicated to immunodiagnostics. DPC's
product menu includes over 75 immunoassays and more than 375
specific allergens and allergy panels. In addition, DPC addresses
the chemistry and laboratory automation testing needs of its
customers through partnerships with manufacturers of chemistry
systems and reagents. The combined chemistry and immunoassay menu
is one of the largest and most diversified available, covering most
laboratory tests requested. DPC also designs and manufactures
automated laboratory instrumentation, which provides fast, accurate
results while reducing labor and reagent costs. DPC sells its
products to hospitals, clinics and laboratories in more than 100
countries. Additional Company information can be found on DPC's
website at www.dpcweb.com. Except for the historical information
contained herein, this press release contains forward-looking
statements that involve risks and uncertainties that could cause
actual results to differ materially. These factors include
governmental or other action relating to the Company's Chinese
affiliate; the rate of customer demand for the Company's products;
the Company's ability to successfully market new and existing
products; its dependence on certain suppliers; domestic and foreign
government regulation; its ability to keep abreast of technological
innovations and to translate them into new products; competition;
political and economic instability in certain markets including the
movements of foreign currencies relative to the dollar; and other
risks and uncertainties disclosed from time to time in the
Company's SEC reports and filings. -0- *T DIAGNOSTIC PRODUCTS
CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME
(unaudited) (Amounts in Thousands, Except Per Share Data) Three
Months Ended Nine Months Ended September 30, September 30,
------------------- ------------------- 2005 2004 2005 2004
--------- --------- --------- --------- SALES: Non-Affiliated
Customers $111,105 $100,742 $337,944 $300,465 Unconsolidated
Affiliates 5,225 8,221 16,756 25,049 --------- --------- ---------
--------- Total Sales 116,330 108,963 354,700 325,514 COST OF SALES
50,499 46,432 149,422 137,270 --------- --------- ---------
--------- Gross Profit 65,831 62,531 205,278 188,244 OPERATING
EXPENSES: Selling 20,215 19,126 61,907 57,235 Research and
Development 12,524 11,188 37,642 33,637 General and Administrative
11,977 11,752 38,120 32,475 Gain on Sale of Product Line (343)
(343) Equity in Income of Affiliates (1,752) (1,705) (7,887)
(6,535) --------- --------- --------- --------- OPERATING
EXPENSES-NET 42,621 40,361 129,439 116,812 --------- ---------
--------- --------- OPERATING INCOME 23,210 22,170 75,839 71,432
Interest/Other Income (Expense)-Net 1,084 1,334 2,270 781 ---------
--------- --------- --------- INCOME BEFORE INCOME TAXES AND
MINORITY INTEREST 24,294 23,504 78,109 72,213 PROVISION FOR INCOME
TAXES 6,655 6,573 22,316 21,186 MINORITY INTEREST 587 414 1,724 434
--------- --------- --------- --------- NET INCOME $17,052 $16,517
$54,069 $50,593 ========= ========= ========= ========= EARNINGS
PER SHARE: BASIC $0.58 $0.57 $1.84 $1.74 DILUTED $0.56 $0.55 $1.79
$1.69 WEIGHTED AVERAGE SHARES OUTSTANDING: BASIC 29,395 29,120
29,329 29,049 DILUTED 30,212 29,853 30,133 29,880 *T
Grafico Azioni Diagnostic Products (NYSE:DP)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Diagnostic Products (NYSE:DP)
Storico
Da Giu 2023 a Giu 2024